Tao Derrick L, Kartika Thomas, Tran Audrey, Prasad Vinay
Division of Internal Medicine, Oregon Health & Science University, USA.
School of Medicine, Oregon Health & Science University, USA.
Eur J Cancer. 2020 Nov;139:20-26. doi: 10.1016/j.ejca.2020.04.037. Epub 2020 Sep 18.
The advancement of therapeutic strategies in oncology such as precision oncology has generated significant interest in better estimating the response of modern phase I cancer clinical trials. These estimates have varied widely. In this commentary, we provide an umbrella review of phase I response rates and discuss methodological reasons for variation in prior estimates which include limited use of unpublished data, the inclusion of expansion cohorts that artificially raise response rates of cumulative response rates, varying enrolment of haematologic malignancies, and increased next in class drugs.
肿瘤学治疗策略的进步，如精准肿瘤学，引发了人们对更好地评估现代I期癌症临床试验反应的浓厚兴趣。这些评估差异很大。在这篇评论中，我们对I期反应率进行了综合综述，并讨论了先前评估存在差异的方法学原因，包括未发表数据的使用有限、纳入人为提高累积反应率的扩大队列、血液系统恶性肿瘤的不同入组情况以及同类新药的增加。
